Is Now The Time To Put Puma Biotechnology (NASDAQ:PBYI) On Your Watchlist?
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
Insider Sale: President and CEO of $PBYI (PBYI) Sells 33,841 Shares
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why
Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
Puma Biotechnology's NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer With a HER2 Mutation
EmotionOutofEquation : analysts fooled me last year with target $14 volatility luckily didn’t bet big size that was 2/3 year projection may be good luck anyway fundamentally buy signal here